BACKGROUND AND OBJECTIVE: To compare images acquired by Stratus time domain optical coherence tomography (OCT) (Carl Zeiss Meditec, Dublin, CA) and Cirrus spectral domain OCT (Carl Zeiss Meditec) in cases of bilateral type 2 idiopathic perifoveal telangiectasia. PATIENTS AND METHODS: Twenty-three eyes of 12 patients with type 2 idiopathic perifoveal telangiectasia were examined on the same day with both OCT systems. RESULTS: Foveal cystoid spaces were detected in more eyes by Cirrus than Stratus OCT (19 of 23 vs 13 of 23). Disruptions of the inner segment/outer segment photoreceptor line were detected with both systems but were only quantified on Cirrus images. Thinning of central foveal thickness was established by both, but only Cirrus OCT measured outer retinal thinning on the temporal compared to the nasal side of the fovea. CONCLUSIONS: Spectral domain OCT could become a new noninvasive tool for facilitating early diagnosis of type 2 idiopathic perifoveal telangiectasia and for following its evolution and the effects of any treatments.
BACKGROUND AND OBJECTIVE: To compare images acquired by Stratus time domain optical coherence tomography (OCT) (Carl Zeiss Meditec, Dublin, CA) and Cirrus spectral domain OCT (Carl Zeiss Meditec) in cases of bilateral type 2 idiopathic perifoveal telangiectasia. PATIENTS AND METHODS: Twenty-three eyes of 12 patients with type 2 idiopathic perifoveal telangiectasia were examined on the same day with both OCT systems. RESULTS: Foveal cystoid spaces were detected in more eyes by Cirrus than Stratus OCT (19 of 23 vs 13 of 23). Disruptions of the inner segment/outer segment photoreceptor line were detected with both systems but were only quantified on Cirrus images. Thinning of central foveal thickness was established by both, but only Cirrus OCT measured outer retinal thinning on the temporal compared to the nasal side of the fovea. CONCLUSIONS: Spectral domain OCT could become a new noninvasive tool for facilitating early diagnosis of type 2 idiopathic perifoveal telangiectasia and for following its evolution and the effects of any treatments.
Authors: Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird Journal: Invest Ophthalmol Vis Sci Date: 2012-09-14 Impact factor: 4.799
Authors: Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird Journal: Invest Ophthalmol Vis Sci Date: 2012-11-29 Impact factor: 4.799
Authors: Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl Journal: Prog Retin Eye Res Date: 2012-12-03 Impact factor: 21.198